SunTrust analyst says that the recent weakness in bluebird bio's stock may have been partially caused by an FDA document on Novartis' CAR T product for r/r B-cell ALL. The analyst says that the "tone" of the document was "neutral," while bluebird's bb2121 has a "differentiated...strong safety profile." Nash notes that the document discusses Novartis' manufacturing process control and says that bluebird bio's experience should give it "strong expertise in manufacturing." He calls bluebird's recent weakness unjustified and keeps a $108 price target and a Buy rating on bluebird.